Circulating Tumour DNA in Muscle-Invasive Bladder Cancer.
View/ Open
Date
2018-08-29ICR Author
Author
Tan, MP
Attard, G
Huddart, RA
Type
Journal Article
Metadata
Show full item recordAbstract
Circulating tumour DNA (ctDNA) is an attractive tool in cancer research, offering many advantages over tissue samples obtained using traditional biopsy methods. There has been increasing interest in its application to muscle-invasive bladder cancer (MIBC), which is recognised to be a heterogeneous disease with overall poor prognosis. Using a range of platforms, studies have shown that ctDNA is detectable in MIBC and may be a useful biomarker in monitoring disease status and guiding treatment decisions in MIBC patients. Currently, with no such predictive or prognostic biomarkers in clinical practice to guide treatment strategy, there is a real unmet need for a personalised medicine approach in MIBC, and ctDNA offers an exciting avenue through which to pursue this goal. In this article, we present an overview of work to date on ctDNA in MIBC, and discuss the inherent challenges present as well as the potential future clinical applications.
Collections
Subject
Animals
Humans
Urinary Bladder Neoplasms
Biomarkers, Tumor
Circulating Tumor DNA
Research team
Clinical Academic Radiotherapy (Horwich)
Clinical Academic Radiotherapy (Huddart)
Language
eng
Date accepted
2018-08-27
License start date
2018-08-29
Citation
International journal of molecular sciences, 2018, 19 (9)
Publisher
MDPI